I.V. lidocaine may be safe, efficacious for pediatric status migraine

New research points to I.V. lidocaine as a viable approach for treating status migraine in children and teens. A total of 26 minors with the condition were included in the investigation, each of them having been in the hospital for a mean 4.6 days. It took 19.3 hours on average to completely resolve pain with lidocaine bolus or infusion.

New research points to I.V. lidocaine as a viable approach for treating status migraine in children and teens. A total of 26 minors with the condition were included in the investigation, each of them having been in the hospital for a mean 4.6 days. It took 19.3 hours on average to completely resolve pain with lidocaine bolus or infusion. The rate of pain resolution was 90.3%, but more than half of study participants suffered a relapse. For certain cases, "I.V. lidocaine may be a safe and effective treatment for children and adolescents with status migraine," according to the study authors, who reported their findings in Pediatric Critical Care Medicine. "Larger prospective studies need to be done not only to evaluate safety and efficacy but also the analgesic longevity of I.V. lidocaine post discharge."